News | February 02, 2026
Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025
The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
